Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 4, 2005, Pages 547-554

  Jorquera, Francisco ^b   Monte, Maria J ^a   Guerra, Jose ^b   Sanchez Campos, Sonia ^c   Merayo, Jose A ^a   Olcóz, Jose L ^b   González Gallego, Javier ^c   Marin, Jose J G ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Department of Gastroenterology   (Spain)

^c UNIVERSITY OF LEÓN   (Spain)

Author keywords

Interferon; Liver; Non response; Ribavirin; Virus

Indexed keywords

3ALPHA HYDROXYL BILE ACID; ANTIVIRUS AGENT; BILE ACID; BIOLOGICAL MARKER; CHENODEOXYCHOLIC ACID; CHOLIC ACID; FERRITIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GAS CHROMATOGRAPHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MASS SPECTROMETRY; MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TURBIDIMETRY;

EID: 19944363835     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03725.x     Document Type: Article

References (47)

1. Iino S. Natural history of hepatitis B and C virus infections. Oncology 2002; 62 (Suppl. 1): 18-23.
2. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-25.
3. Ideo G, Bellobuono A. New therapies for the treatment of chronic hepatitis C. Curr. Pharm. Des. 2002; 8: 959-66.
4. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
5. Carreño V. Present treatment expectations and risks of chronic hepatitis C. Clin. Microbiol. Infect. 2002; 8: 74-9.
6. Xin W, Wang JH. Treatment of duck hepatitis B virus by antisense poly-2′-O-(2,4-dinitrophenyl)-oligoribonucleotides. Antisense Nucleic Acid Drug Dev. 1998; 8: 459-68.
7. Gumina G, Song GY, Chu CK. Advances in antiviral agents for hepatitis B virus. Antivir. Chem. Chemother. 2001; 12 (Suppl. 1): 93-117.
8. Christopherson C, Lu SD, Kwok S. Laboratory markers of antiviral activity. Antivir. Ther. 1998; 3: 247-50.
9. Arns PA, Adedoyin A, DiBisceglie AM et al. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis. Clin. Pharmacol. Ther. 1997; 62: 527-37.
10. Jorquera F, Almar M, Diaz-Golpe V, Olcoz JL, Garcia-Fernandez A, Gonzalez-Gallego J. Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy. Am. J. Gastroenterol. 2001; 96: 2456-61.
11. Arber N, Konikoff FM, Moshkowitz M et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatits C from other chronic liver diseases. Dig. Dis. Sci. 1994; 39: 2656-9.
12. Mannes GA, Stellaard F, Paumgartner G. Increased serum bile acids in cirrhosis with normal transaminases. Digestion 1982; 25: 217-21.
13. Simko V, Michael S. Bile acid levels in diagnosing mild liver disease. Fasting and postcholecystokinetic values. Arch. Intern. Med. 1986; 146: 695-7.
14. Ferraris R, Fiorentini MT, Galatola G, Rolfo P, De la Pierre M. Diagnostic value of serum immunoreactive conjugated cholic or chenodeoxycholic acids in detecting hepatobiliary diseases. Comparison with levels of 3alpha-hydroxy bile acids determined enzymatically and with routine liver tests. Dig. Dis. Sci. 1987; 32: 817-23.
15. Korman MG, Hofmann AF, Summerskill WHJ. Assessment of activity in chronic active liver disease. Serum bile acids compared with conventional tests and histology. N. Engl. J. Med. 1974; 290: 1399-402.
16. Monroe PS, Baker AL, Schneider JF, Krager PS, Klein PD, Schoeller D. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982; 2: 317-22.
17. Mannes GA, Thieme C, Stellaard F, Wang T, Sauerbruch T, Paumgartner G. Prognostic significance of serum bile acids in cirrhosis. Hepatology 1986; 6: 50-3.
18. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1493-9.
19. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1485-92.
20. Chan SW, McOmish F, Holmes EC et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J. Gen. Virol. 1992; 73: 1131-6.
21. McOmish F, Yap PL, Dow BC et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J. Clin. Microb. 1994; 32: 884-92.
22. Davidson F, Simmonds P, Ferguson JC et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J. Gen. Virol. 1995; 76: 1197-204.
23. Knodell RG, Ishak KG, Black WC et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
24. Setchell KDR, Worthington JA. Rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse phase octadecylsilane-bonded silica cartridges. Clin. Chim. Acta 1982; 125: 135-44.
25. Talalay P. Enzymatic analysis of steroid hormones. Meth. Biochem. Anal. 1960; 8: 119-43.
26. Mashige U, Imai K, Osuga TA. Simple and sensitive assay of total serum bile acids. Clin. Chim. Acta 1976; 70: 79-86.
27. Monte MJ, Morales AI, Arevalo M, Alvaro I, Macias RIR, Marin JJG. Reversible impairment of neonatal hepatobiliary function by maternal cholestasis. Hepatology 1996; 23: 1208-17.
28. Shoda J, Osuga T, Matsuura K et al. Concurrent occurrence of 3-beta, 12-alpha-dihydroxy-5-cholenoic acid associated with 3-beta-hydroxy-5-cholenoic acid and their preferential urinary excretion in liver diseases. J. Lipid Res. 1989; 30: 1233-42.
29. Malavolti M, Fromm H, Nsien E et al. Formation, absorption, and biotransformation of delta6-lithocholenic acid in humans. Am. J. Physiol. 1993; 264: G163-71.
30. Alme B, Bremmelgaard A, Sjovall J, Thomassen P. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatography-mass spectrometry. J. Lipid Res. 1977; 18: 339-62.
31. El-Mir MY, Badia MD, Luengo N, Monte MJ, Marin JJG. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clin. Sci. 2001; 100: 499-508.
32. Tappero G, Ballare M, Farina M, Negro F. Severe anemia following combined-interferon/ribavirin therapy of chronic hepatitis C. J. Hepatol. 1998; 29: 1033-4.
33. Gamma C, Giunta M, Chemello L et al. Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data. Hepatology 1999; 30: 801-7.
34. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J. Hepatol. 1999; 31 (Suppl. 1): 237-43.
35. Pol S, Nalpas B, Bourliere M et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype 1b related chronic hepatitis C. Hepatology 2000; 31: 1338-44.
36. Poynard T, McHutchinson JG, Goodman Z, Ling MH, Albrecht J. Is and 'A la Carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?. The ALGOVIRC Project Group. Hepatology 2000; 31: 211-18.
37. Shima T, Tada H, Morimoto M et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol. Hepatol. 2000; 15: 294-9.
38. Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. J. Gastroenterol. Hepatol. 1999; 14: 946-59.
39. Burgart LJ. Cholangitis in viral disease. Mayo Clin. Proc. 1998; 73: 479-82.
40. Alberti A, Bortolotti F. Hepatitis C. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology, 2nd edn. Oxford: Oxford University Press, 1999; 903-22.
41. Lebovics E, Seif F, Kim D et al. Pruritus in chronic hepatitis C. Association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig. Dis. Sci. 1997; 42: 1049-99.
42. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, DiBisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig. Dis. Sci. 1998; 43: 2177-83.
43. Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001; 21: 247-53.
44. Zollner G, Fickert P, Zenz R et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33: 633-46.
45. Makino I, Hashimoto H, Shinozaki K, Yoshino K, Nakagawa S. Sulfated and nonsulfated bile acids in urine, serum, and bile of patients with hepatobiliary diseases. Gastroenterology 1975; 68: 545-53.
46. Takikawa H, Beppu T, Seyama Y, Sugimoto T. Glucuronidated and sulfated bile acids in serum of patients with acute hepatitis. Dig. Dis. Sci. 1986; 31: 487-91.
47. Simko V, Michael S. Urinary bile acids in population screening for inapparent liver disease. Hepatogastroenterology 1998; 45: 1706-14.